Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 2015. The report serves as a notification of transactions involving directors and connected persons in accordance with DTR 3.1.4 R(1)(c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction regarding the GSK 401K plan.
Material Changes
On November 12, 2015, an increase in the notional allocation of GSK American Depositary Shares (ADSs) occurred within the GSK 401K plan following the revaluation of the cash element of the notional investment. The transaction price was $40.05 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items beyond the disclosed director transaction.
Important Facts for Investors
- Transaction Date: November 12, 2015.
- Transaction Price: $40.05 per ADS.
- Director Activity: Dr. M. Slaoui received a notional allocation of 24 ADSs.
- Connected Person Activity: Dr. K. Slaoui (connected to Dr. M. Slaoui) received a notional allocation of 1 ADS.
- Context: These allocations resulted from the revaluation of the cash element within the GSK 401K plan, not direct market purchases.